Norditropin

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Metabolic SyndromeNoonan Syndrome

70 competitors in Metabolic Syndrome

#DrugCompanyPhaseTrials

1

Crestor

AstraZeneca

Approved

62

Actos

Takeda

Approved

53

Cosentyx

Novartis

Approved

34

Avandia

Jazz Pharmaceuticals

Approved

25

Bayer Aspirin

Bayer

Approved

16

Uloric

Takeda

Approved

17

Victoza

Novo Nordisk

Approved

18

Geodon

Pfizer

Approved

19

Ozempic

Novo Nordisk

Approved

110

Niacor

AbbVie

Approved

—Show 37 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Growth3 trials

Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency

Completed·—·Phase 1/2·NCT03288103·22 enrolled

Luteal Phase Commencing of Growth Hormone

Completed·GGulhane School of Medicine··NCT00561769·61 enrolled

Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.

Completed·UUniversity of Aarhus·N/A·NCT02077348·9 enrolled

Treatment2 trials

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

Completed·Novo Nordisk·Phase 3·NCT03811535·200 enrolled

A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.

Completed·Novo Nordisk·Phase 3·NCT04970654·110 enrolled

Growth Hormone Deficiency2 trials

Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children

Completed·XXiamen Amoytop Biotech Co., Ltd.·Phase 2/3·NCT04513171·434 enrolled

A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

Completed·Novo Nordisk·Phase 3·NCT03075644·62 enrolled

Children1 trial

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

Active, not recruiting·Novo Nordisk·Phase 3·NCT05330325·412 enrolled

Noonan syndrome1 trial

French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome

Enrolling by invitation·Novo Nordisk··NCT05308927·221 enrolled

3 more indications

Metabolic Syndrome1 trial

Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.

Withdrawn·OOregon Health and Science University·N/A·NCT00720616

Born Small for Gestational Age1 trial

A Dose-finding Trial Evaluating the Effect and Safety of Once-weekly Treatment of Somapacitan Compared to Daily Norditropin® in Children With Short Stature Born Small for Gestational Age With no Catch-up Growth by 2 Years of Age or Older

Active, not recruiting·Novo Nordisk·Phase 2·NCT03878446·62 enrolled

Unspecified1 trial

Growth Hormone Administration and the Human Immune System

Completed·NNational Institute on Aging (NIA)·Phase 1·NCT00663611·66 enrolled

Details

Drug Info

Related News